Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy

Inclusion Criteria

• •1. Signed informed consent by patient
• •2. Age above 18 years
• •3. Child-Pugh A or B cirrhosis
• •4. Eastern Cooperative Oncology Group performance (ECOG) score 2 or below
• •5. No serious concurrent medical illness
• •6. Histologically or cytologically proven malignant liver tumor, or lesions of size 1 to 2 cm, with typical features of hepatocellular carcinoma (HCC) on two dynamic imaging techniques, or lesions larger than 2cm, with typical features on one dynamic imaging techniques, or lesions larger than 2cm with Apha Fetal Protein (AFP) level \> 200 ug/L
• •7. Inoperable HCC due to patient or tumor factors, without extra-hepatic involvement on Chest X-ray (CXR) and CT
• •8. Massive expansive tumor type of HCC with measurable lesion on CT
• •9. Recurrent intrahepatic HCC after surgical resection or local ablation
• •10. Metastatic liver tumor with well-defined margin
• •11. Tumor size \<= 3cm in largest dimension
• •12. Tumor number \<= 3
• •1. Signed informed consent by patient
• •2. Age older than 18 years.
• •3. Any kind of histologically or radiologically diagnosed malignant pancreatic tumor.
• •4. Tumor size \<= 3cm in largest dimension
• •5. Surgical treatment is considered not an option because of patient factors or tumor factors, such as those with vascular encasement or regional lymph node metastasis
• •6. Locally recurrent pancreatic tumor after surgical resection
• •7. Karnofsky's performance status of 50% or greater.
• •8. Life expectancy greater than 3 months.
• •9. Normal coagulation profile (INR \<1.5; platelet count \>50 10\^9/L).
• •10. Willingness and ability to complete follow-up interviews and imaging investigations following the treatment.